Physostigmine and lithium response in the schizophrenias

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Conflicting research exists on whether cholinomimetics can reduce schizophrenic symptoms.
• Physostigmine is a cholinomimetic agent with potential effects on psychosis.

Purpose of the Study:

• To investigate the effects of physostigmine on schizophrenic symptoms in patients with schizophrenic-like illness.
• To determine if response to physostigmine predicts response to lithium treatment.

Main Methods:

• Administered physostigmine infusions to patients with schizophrenic-like illness.
• Assessed changes in psychiatric symptoms using the Brief Psychiatric Rating Scale.
• Subgrouped patients based on antipsychotic response to lithium after physostigmine infusion.

Main Results:

• Patients showing temporary improvement in thinking disturbance after physostigmine infusion subsequently responded to lithium.
• Patients not improving after physostigmine infusion did not respond to lithium.
• Physostigmine's effects on symptoms were temporary.

Conclusions:

• Some schizophrenic-like illnesses may share biological similarities with mania.
• Response to physostigmine may predict lithium response in specific patient subgroups.
• Cholinomimetic and lithium responses suggest a potential biological overlap between schizophrenia-like disorders and mania.